NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting - Seite 2
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus or physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostic Division also serves pharmaceutical clients in clinical trials and drug development.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.
Lesen Sie auch
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326587441/en/
The Neogenomics Stock at the time of publication of the news with a fall of -0,71 % to 14,00USD on Tradegate stock exchange (27. März 2024, 11:05 Uhr).